New patient studies surrounding Retatrutide , specifically the high-dose formulation branded as ZPHC, reveal a significant benefit on weight reduction and related chronic illnesses . Scientists posit that this combined agonist , influencing both GLP-1 and GIP pathways , could offer a major breakthrough in the treatment of obesity and related disea